Skip to main content

Search

Welcome to Janssen Canada

VISIT JANSSEN GLOBAL

Title

Media

17, October, 2018

Toronto

Health Canada has approved INVOKANA®* (canagliflozin) for reduction of major adverse cardiovascular events (MACE), the first SGLT2 inhibitor in Canada to receive this indication1

04, July, 2018

Toronto, Ontario

Health Canada Approves ERLEADA™* (apalutamide tablets), the First Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer

27, March, 2018

Toronto

Prince Edward Island drug plan now includes REMICADE® for the treatment of multiple autoimmune diseases

15, February, 2018

Toronto, Ontario

Health Canada Approves New Indication for ZYTIGA^® (abiraterone acetate), Broadening its Use for Treatment of Newly Diagnosed Metastatic Prostate Cancer

15, November, 2017

Toronto

Janssen Inc. Announces Health Canada Approval of TREMFYA™ (guselkumab) for the Treatment of Adult Moderate to Severe Plaque Psoriasis

31, October, 2017

Toronto

Janssen Inc. Announces IMBRUVICA® (ibrutinib) as the First Approved Treatment for Chronic Graft-Versus-Host Disease (cGVHD) Granted by Health Canada Priority Review

25, October, 2017

Toronto

Janssen Inc. Announces Health Innovation Partnership with Memorial University of Newfoundland

12, June, 2017

Toronto, Ontario

INVOKANA® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction, and Stroke in the CANVAS Program

27, April, 2017

Toronto, Ontario

Janssen Inc. Applauds Government of Ontario Decision to Increase Funding For Drug Budget

17, April, 2017

Toronto, Ontario

Janssen Inc. Receives Health Canada Approval of DARZALEX® (daratumumab) by Priority Review for Patients with Multiple Myeloma Who Have Had At Least One Prior Therapy